Literature DB >> 24621284

Hepatosplenic T-cell lymphoma, immunosuppressive agents and biologicals: what are the risks?

K Subramaniam1, D Yeung, F Grimpen, J Joseph, K Fay, M Buckland, D Talaulikar, J Elijah, A C Clarke, P Pavli, J Moore.   

Abstract

We present three cases of the rare hepatosplenic T-cell lymphoma (HSTCL); two patients suffering from Crohn disease who developed HSTCL on azathioprine without exposure to biologicals, and a third patient who had psoriasis treated using etanercept, cyclosporine and methotrexate. The evidence for an association between HSTCL and immunosuppressive drugs and biologicals is reviewed. We argue for improved pharmacovigilance processes to help determine the benefit to risk ratios for the use of these and other new agents.
© 2014 The Authors; Internal Medicine Journal © 2014 Royal Australasian College of Physicians.

Entities:  

Keywords:  biologicals; hepatosplenic T-cell lymphoma; immunosuppression; inflammatory bowel disease; psoriasis

Mesh：

Substances：

Year:  2014        PMID： 24621284     DOI： 10.1111/imj.12363

Source DB:  PubMed          Journal:  Intern Med J        ISSN： 1444-0903            Impact factor:   2.048


  8 in total

1.  Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-α inhibitor therapy and literature review.

Authors:  Mariko Yabe; L Jeffrey Medeiros; Yahya Daneshbod; Masoud Davanlou; Carlos E Bueso-Ramos; Elisa J Moran; Ken H Young; Roberto N Miranda
Journal:  Ann Diagn Pathol       Date:  2016-10-18       Impact factor: 2.090

2.  Hepatosplenic T cell lymphoma presenting as multiorgan failure.

Authors:  Puraskar Pateria; Annalise Martin; Tze Sheng Khor; Vanoo Jayasekeran
Journal:  BMJ Case Rep       Date:  2019-03-21

3.  Hepatosplenic T cell lymphoma: a unifying entity in a patient with hemolytic anemia, massive splenomegaly, and liver dysfunction.

Authors:  Marianna Mavilia; Agnes McAuliffe; Safina Hafeez; Haleh Vaziri
Journal:  Clin J Gastroenterol       Date:  2018-05-15

4.  Safety and efficacy of azathioprine in immune thrombocytopenia.

Authors:  Kundan Mishra; Suman Pramanik; Rajeev Sandal; Aditya Jandial; Kamal Kant Sahu; Kanwaljeet Singh; Sanjeev Khera; Ashok Meshram; Harshit Khurana; Venkatesan Somasundaram; Rajiv Kumar; Rajan Kapoor; Tarun Verma; Sanjeevan Sharma; Jasjit Singh; Satyaranjan Das; Tathagat Chaterjee; Ajay Sharma; Velu Nair
Journal:  Am J Blood Res       Date:  2021-06-15

5.  Use of case reports and the Adverse Event Reporting System in systematic reviews: overcoming barriers to assess the link between Crohn's disease medications and hepatosplenic T-cell lymphoma.

Authors:  Saranya A Selvaraj; Elizabeth Chairez; Lisa M Wilson; Mark Lazarev; Eric B Bass; Susan Hutfless
Journal:  Syst Rev       Date:  2013-07-05

6.  Resected Hepatocellular Carcinoma in a Patient with Crohn's Disease on Azathioprine.

Authors:  Valérie Heron; Kyle Joshua Fortinsky; Gillian Spiegle; Nir Hilzenrat; Andrew Szilagyi
Journal:  Case Rep Gastroenterol       Date:  2016-05-19

7.  Survival Analysis of Hepatosplenic T Cell Lymphoma: A Population-Based Study Using SEER.

Authors:  Yajun Li; Kailin Chen; Chaohui Zuo; Ruolan Zeng; Yizi He; Xiaoyan Chen; Ling Xiao; Hui Zhou
Journal:  Int J Gen Med       Date:  2021-11-17

Review 8.  Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease.

Authors:  Ray K Boyapati; Joana Torres; Carolina Palmela; Claire E Parker; Orli M Silverberg; Sonam D Upadhyaya; Tran M Nguyen; Jean-Frédéric Colombel
Journal:  Cochrane Database Syst Rev       Date:  2018-05-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.